Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Skin Cancer: Prevention, Diagnosis and Treatment
share announcement

Skin Cancer: Prevention, Diagnosis and Treatment

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Dermatology".

Deadline for manuscript submissions: 20 March 2025 | Viewed by 7084

Special Issue Editors

Dr. Athanassios A. Kyrgidis

E-Mail Website
Guest Editor
Department of Oral & Maxillofacial Surgery, Aristotle University of Thessaloniki, R.G.H. "George Papanikolaou", Exohi, Thessaloniki, Greece
Interests: skin cancer; head and neck cancer; melanoma; clinical pharmacology; patient-reported-outcome-measures; clinical biomarkers; prognostic factors; epidemiology; oral and maxillofacial surgery
Special Issues, Collections and Topics in MDPI journals
Dr. Aimilios Lallas

E-Mail Website
Guest Editor
First Department of Dermatology, School of Medicine, Faculty of Health Sciences, Aristotle University, Thessaloniki, Greece
Interests: melanoma; skin cancer; basal cell carcinoma; squamous cell carcinoma; dermoscopy; dermatoscopy; diagnosis; nevi
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Skin cancer incidence is increasing. Different forms of skin cancer include melanoma, basal cell carcinoma, and squamous cell carcinoma, each with varying degrees of severity and treatment requirements. The economic impact of skin cancer is substantial, as it involves not only the direct expenses associated with diagnosis and treatment, but also the long-term management of survivors and the prevention efforts required to reduce its incidence. Consequently, healthcare systems require considerable financial resources, specialized personnel, and infrastructure to meet the growing demand for skin cancer care and mitigate its profound impact on patients and society as a whole.

Skin cancer can significantly impact the quality of life of individuals, as it may lead to physical discomfort, disfigurement, emotional distress, and limitations in daily activities due to the disease itself or the necessary treatments. The treatment outcomes are important as new treatments emerge that need to be administered to patients on the grounds of sufficient evidence.

Accordingly, a Special Issue called “Skin Cancer: Prevention, Diagnosis and Treatment” is announced. This Special Issue calls for original research and systematic reviews that investigate clinical, dermoscopic, diagnostic, or therapeutic features of skin cancers and their impact on the quality of life of affected patients.

Dr. Athanassios A. Kyrgidis
Dr. Aimilios Lallas
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • skin cancer
  • melanoma
  • squamous cell carcinoma
  • basal cell carcinoma
  • clinical biomarkers
  • dermoscopy
  • quality of life

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

25 pages, 1300 KiB  
Article
Primary Cutaneous Melanoma—Management in 2024
by Anthony Joseph Dixon, Michael Sladden, Christos C. Zouboulis, Catalin M. Popescu, Alexander Nirenberg, Howard K. Steinman, Caterina Longo, Zoe Lee Dixon and Joseph Meirion Thomas
J. Clin. Med. 2024, 13(6), 1607; https://doi.org/10.3390/jcm13061607 - 11 Mar 2024
Cited by 3 | Viewed by 4124
Abstract
Background: Maximizing survival for patients with primary cutaneous melanomas (melanomas) depends on an early diagnosis and appropriate management. Several new drugs have been shown to improve survival in high-risk melanoma patients. Despite well-documented guidelines, many patients do not receive optimal management, particularly [...] Read more.
Background: Maximizing survival for patients with primary cutaneous melanomas (melanomas) depends on an early diagnosis and appropriate management. Several new drugs have been shown to improve survival in high-risk melanoma patients. Despite well-documented guidelines, many patients do not receive optimal management, particularly when considering patient age. Objective: to provide an update on melanoma management from the time of the decision to biopsy a suspicious skin lesion. Methods: We reviewed melanoma-management research published between 2018 and 2023 and identified where such findings impact and update the management of confirmed melanomas. Pubmed, Google Scholar, Ovid and Cochrane Library were used as search tools. Results: We identified 81 publications since 2017 that have changed melanoma management; 11 in 2018, 12 in 2019, 10 in 2020, 12 in 2021, 17 in 2022 and 18 in 2023. Discussion: Delayed or inaccurate diagnosis is more likely to occur when a partial shave or punch biopsy is used to obtain the histopathology. Wherever feasible, a local excision with a narrow margin should be the biopsy method of choice for a suspected melanoma. The Breslow thickness of the melanoma remains the single most important predictor of outcome, followed by patient age and then ulceration. The BAUSSS biomarker, (Breslow thickness, Age, Ulceration, Subtype, Sex and Site) provides a more accurate method of determining mortality risk than older currently employed approaches, including sentinel lymph node biopsy. Patients with metastatic melanomas and/or nodal disease should be considered for adjuvant drug therapy (ADT). Further, high-risk melanoma patients are increasingly considered for ADT, even without disease spread. Invasive melanomas less than 1 mm thick are usually managed with a radial excision margin of 10 mms of normal skin. If the thickness is 1 to 2 mm, select a radial margin of 10 to 20 mm. When the Breslow thickness is over 2 mm, a 20 mm clinical margin is usually undertaken. In situ melanomas are usually managed with a 5 to 10 mm margin or Mohs margin control surgery. Such wide excisions around a given melanoma is the only surgery that can be regarded as therapeutic and required. Patients who have had one melanoma are at increased risk of another melanoma. Ideal ongoing management includes regular lifelong skin checks. Total body photography should be considered if the patient has many naevi, especially when atypical/dysplastic naevi are identified. Targeted approaches to improve occupational or lifestyle exposure to ultraviolet light are important. Management also needs to include the consideration of vitamin D supplementary therapy. Full article
(This article belongs to the Special Issue Skin Cancer: Prevention, Diagnosis and Treatment)
►▼ Show Figures

Figure 1

Other

Jump to: Research

12 pages, 1337 KiB  
Systematic Review
Sentinel Lymph Node Biopsy in Atypical Spitz Tumor: A Systematic Review
by Marcodomenico Mazza, Francesco Cavallin, Elisa Galasso, Paolo Del Fiore, Rocco Cappellesso, Fortunato Cassalia, Saveria Tropea, Irene Russo, Mauro Alaibac and Simone Mocellin
J. Clin. Med. 2024, 13(11), 3232; https://doi.org/10.3390/jcm13113232 - 30 May 2024
Viewed by 984
Abstract
Background: Atypical Spitz tumor (AST) is an intermediate category among Spitz melanocytic neoplasms. Sentinel node biopsy (SNB) has been proposed in the clinical management of AST patients, but this approach remains the subject of debate. This systematic review aims to summarize the available [...] Read more.
Background: Atypical Spitz tumor (AST) is an intermediate category among Spitz melanocytic neoplasms. Sentinel node biopsy (SNB) has been proposed in the clinical management of AST patients, but this approach remains the subject of debate. This systematic review aims to summarize the available evidence on SNB procedures in AST patients. Methods: A comprehensive search was conducted, including MEDLINE/Pubmed, EMBASE, and SCOPUS, through April 2023. Case series, cohort studies, and case–control studies of AST patients were eligible for inclusion. PRISMA guidelines were followed. Results: Twenty-two studies with a total of 756 AST patients were included. The pooled SNB prevalence was 54% (95% CI 32 to 75%), with substantial heterogeneity (I2 90%). The pooled SNB+ prevalence was 35% (95% CI 25 to 46%) with moderate heterogeneity (I2 39%). Lymphadenectomy was performed in 0–100% of SNB+ patients. Overall survival rates ranged from 93% to 100%, and disease-free survival ranged from 87% to 100% in AST patients. Overall and disease-free survival rates were 100% in SNB patients. Pooled survival estimates were not calculated due to the heterogeneous timing of the survival assessment and/or the small size of the subgroups. All studies clearly reported inclusion criteria and measured the condition in a standard way for all participants, but only 50% indicated valid methods for the identification of the condition. Conclusions: The oncologic behavior of AST is related to an almost always favorable outcome. SNB does not seem to be relevant as a staging or prognostic procedure, and its indication remains debatable and controversial. Full article
(This article belongs to the Special Issue Skin Cancer: Prevention, Diagnosis and Treatment)
►▼ Show Figures

Figure 1

14 pages, 6602 KiB  
Systematic Review
Dermoscopy of Umbilical Lesions—A Systematic Review
by Jakub Żółkiewicz, Martyna Sławińska, Urszula Maińska, Roman J. Nowicki, Michał Sobjanek and Luc Thomas
J. Clin. Med. 2024, 13(6), 1790; https://doi.org/10.3390/jcm13061790 - 20 Mar 2024
Cited by 2 | Viewed by 1516
Abstract
Background: The umbilicus is a fibrous remnant located in the centre of the abdomen. Various entities may be encountered in this special anatomical location; however, little is known about their dermoscopic presentation. The aim of this study was to provide a comprehensive [...] Read more.
Background: The umbilicus is a fibrous remnant located in the centre of the abdomen. Various entities may be encountered in this special anatomical location; however, little is known about their dermoscopic presentation. The aim of this study was to provide a comprehensive summary of existing evidence on dermoscopic features of umbilical lesions. Methods: Studies assessing dermoscopic images of umbilical lesions were included in this study. No age, ethnicity or skin phototype restrictions were applied. Papers assessing lesions outside of the umbilical area, lacking dermoscopic images and/or dermoscopic description and not related to the topic were excluded. Embase, Medline and Cochrane Library were searched from inception to the end of May 2023. The Joanna Briggs Institute critical appraisal tools were used to evaluate the risk of bias of the selected studies. The quality and the level of evidence of included studies were assessed according to the Oxford 2011 Levels of Evidence. Thirty-four studies reporting a total of 39 lesions met the inclusion criteria and were included in qualitative analysis. Results: A qualitative synthesis of the following entities was performed: melanoma, nevi, basal cell carcinoma, fibroepithelioma of Pinkus, Sister Mary Joseph nodule, mycosis fungoides, dermatofibroma, endometriosis, epidermal cyst, granuloma, intravascular papillary endothelial hyperplasia, lichen planus, omphalolith, seborrheic keratosis, and syringoma. Conclusions: Dermoscopy is a non-invasive technique that may be useful in the differential diagnosis of umbilical lesions. The main limitations of this study were lack of a high level of evidence in the studies and the lack of uniformity in applied dermoscopic terminology between included studies. Full article
(This article belongs to the Special Issue Skin Cancer: Prevention, Diagnosis and Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop